Devalingam Mahalingam MD

Oncology•Chicago, IL

Assistant Professor, Medicine, University of Texas Medical School, San Antonio

Join to View Full Profile

645 N Michigan AveSte 1006Chicago, IL 60611
Phone+1 210-413-1723
Fax+1 210-450-1150

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 2008 - 2009
National University of Ireland, Galway Faculty of MedicineClass of 2000

Certifications & Licensure

IL State Medical License 2017 - 2026
TX State Medical License 2011 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma Start of enrollment: 2009 Sep 01
Completed
Phase 2
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma Start of enrollment: 2009 Oct 01
Completed
Phase 2
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors Start of enrollment: 2009 Nov 01
Completed
Phase 1
Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors Start of enrollment: 2010 Jan 01
Completed
Phase 1
Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma Start of enrollment: 2013 Apr 01
Completed
Phase 1, Phase 2
A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer Start of enrollment: 2012 Sep 01
Completed
Phase 1, Phase 2
Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer Start of enrollment: 2011 Apr 01
Completed
Phase 2
Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma Start of enrollment: 2013 Jan 01
Completed
Phase 2
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm Start of enrollment: 2013 Jul 01
Completed
Phase 1
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab Start of enrollment: 2014 May 05
Completed
Phase 1
Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma
No longer available
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer Start of enrollment: 2017 Feb 16
ACTIVE_NOT_RECRUITING
PHASE2
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 Start of enrollment: 2019 Jan 29
ACTIVE_NOT_RECRUITING
PHASE2
Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer Start of enrollment: 2018 Nov 14
Terminated
Phase 2
9-ING-41 in Patients with Advanced Cancers Start of enrollment: 2019 Jan 04
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Start of enrollment: 2023 Mar 08
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma (ACC) of all Anatomic Sites of Origin and Other Malignant Sal...
Young Kwang Chae, Richard Duan, Liam Il-Young Chung, Youjin Oh, Borislav Alexiev
Cancer Medicine. 2025-04-01
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.
Ruth Plummer, Mikael H Sodergren, Rose Hodgson, Bríd M Ryan, Nina Raulf
Cell Reports. Medicine. 2025-03-26
Delta Radiomics and Tumor Size: A New Predictive Radiomics Model for Chemotherapy Response in Liver Metastases from Breast and Colorectal Cancer.
Nicolò Gennaro, Moataz Soliman, Amir A Borhani, Linda Kelahan, Hatice Savas
Tomography. 2025-02-20

Grant Support

North American Star ConsortiumUNIVERSITY HEALTH NETWORK2014–2026

Other Languages

Malay